Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma 34Leukemia 34Lymphoma, Follicular 27Melanoma 25Leukemia, Lymphocytic, Chronic, B-Cell 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Lymphoma, Non-Hodgkin 20Leukemia, Myeloid, Acute 20Multiple Myeloma 18Breast Neoplasms 18Lymphoma, Large B-Cell, Diffuse 17Prostatic Neoplasms 15Lymphoma, Mantle-Cell 15Lymphoma, Large-Cell, Immunoblastic 15Neuroblastoma 14Neoplasms, Plasma Cell 13Myelodysplastic Syndromes 13Leukemia, Myelogenous, Chronic, BCR-ABL Positive 13Hodgkin Disease 13Burkitt Lymphoma 13Leukemia, Myeloid, Chronic-Phase 12Neoplasm Metastasis 11Lymphoma, B-Cell, Marginal Zone 11Lung Neoplasms 10Glioblastoma 9Carcinoma, Non-Small-Cell Lung 9Myeloproliferative Disorders 8Leukemia, Myeloid, Accelerated Phase 8Ovarian Neoplasms 7Gliosarcoma 7

Interventions

Trastuzumab 5Carboplatin 4toripalimab 2pertuzumab 2pembrolizumab 2Tretinoin 2Paclitaxel 2Immunotherapy 2Drug Therapy 2Doxorubicin 2Docetaxel 2Cytarabine 2130-nm albumin-bound paclitaxel 2zanidatamab 1venetoclax 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1tislelizumab 1temsirolimus 1talazoparib 1tagraxofusp 1sarilumab 1sargramostim 1pyrotinib 1pexidartinib 1pazopanib 1patritumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Pathologic Complete Response × sargramostim × Clear all
NCT01266083 2024-11-19

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Sellas Life Sciences Group

Phase 2 Completed
22 enrolled 8 charts
LymphoidOther hematologic neoplasm

Pathologic Complete Response, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡